Royal Philips Files 2025 Annual Report Highlighting Growth, Cash Generation and ESG Progress
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Koninklijke Philips ( (PHG) ) has provided an announcement.
On February 19, 2026, Koninklijke Philips N.V. filed a Form 6-K with the U.S. Securities and Exchange Commission to furnish its 2025 Annual Report and related press release to investors. The report, prepared under IFRS and Dutch market rules, details audited group and company financial statements, ESG metrics and governance disclosures, formally placing Philips’ 2025 performance and risk profile on the record for regulators and shareholders.
The 2025 Annual Report highlights EUR 17.8 billion in sales, 2% comparable sales growth, a 12.3% adjusted EBITA margin and EUR 512 million in free cash flow despite cost pressures and tariffs. Philips reports that it improved the lives of 2 billion people, including 253 million in underserved communities, derived 27.9% of sales from circular products and continued strengthening quality, patient safety and operational foundations as part of its multi‑year turnaround.
Additional 2025 milestones include being ranked the highest medtech company in Clarivate’s Top 100 Global Innovators and expanding access to care through long-term partnerships such as in Indonesia. The company also underscored innovation in areas like helium-free 3.0T MRI and AI-powered diagnostic tools, while its CEO emphasized that visible operational gains in 2025 are intended to support sustainable, profitable growth and long-term value creation for stakeholders.
The most recent analyst rating on (PHG) stock is a Buy with a $33.00 price target. To see the full list of analyst forecasts on Koninklijke Philips stock, see the PHG Stock Forecast page.
Spark’s Take on PHG Stock
According to Spark, TipRanks’ AI Analyst, PHG is a Neutral.
PHG scores as moderately attractive, led by a clear 2025 profitability recovery and a supportive technical uptrend. The score is capped by multi-year earnings and cash-flow volatility and meaningful 2026 headwinds (tariffs and Respironics-related uncertainty), while the ~3% dividend provides some valuation support despite a negative P/E.
To see Spark’s full report on PHG stock, click here.
More about Koninklijke Philips
Koninklijke Philips N.V., or Royal Philips, is a Dutch health-technology company focused on medical imaging, connected care solutions and personal health products. With around 65,000 employees worldwide, it targets hospitals, health systems and consumers, emphasizing innovation, circular products and measurable impact on global health and well-being.
Average Trading Volume: 843,881
Technical Sentiment Signal: Buy
Current Market Cap: $29.38B
For an in-depth examination of PHG stock, go to TipRanks’ Overview page.
